Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TGM2 | P21980 | 4/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MLYCD | O95822 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL611770 | 0.80 | MAPT (0.67) | MAPTPOLBSMN1; SMN2RAB9ACHRNB2 | |
| SCHEMBL17523344 | 0.80 | MAPT (0.62) | MAPTPOLBSMN1; SMN2RAB9ACHRNB2 | |
| SCHEMBL27765211 | 0.78 | MAPT (0.60) | MAPTPOLBSMN1; SMN2RAB9ACHRNB2 | |
| SCHEMBL2401634 | 0.78 | MAPT (0.60) | MAPTPOLBSMN1; SMN2RAB9ACHRNB2 | |
| SCHEMBL1392727 | 0.78 | MAPT (0.68) | MAPTPOLBSMN1; SMN2RAB9AALDH1A1 | |
| SCHEMBL29435691 | 0.78 | MAPT (0.68) | MAPTPOLBSMN1; SMN2RAB9AALDH1A1 | |
| SCHEMBL4696975 | 0.77 | MAPT (0.67) | MAPTPOLBSMN1; SMN2RAB9ACHRNB2 | |
| SCHEMBL26641270 | 0.77 | MAPT (0.70) | MAPTPOLBSMN1; SMN2RAB9AALDH1A1 | |
| SCHEMBL6364471 | 0.76 | MAPT (0.60) | MAPTPOLBSMN1; SMN2RAB9ACHRNB2 | |
| SCHEMBL27765218 | 0.76 | MAPT (0.60) | MAPTPOLBSMN1; SMN2RAB9ACHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150099760-A1 | SALT(S) OF 7-CYCLOPENTYL-2-(5-PIPERAZIN-1-YL-PYRIDIN-2-YLAMINO)-7H-PYRROLO[2,3-D]PYRIMIDINE-6-CARBOXYLIC ACID DIMETHYLAMIDE AND PROCESSES OF MAKING THEREOF | NOVARTIS AG (CH) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099760-A1 | SALT(S) OF 7-CYCLOPENTYL-2-(5-PIPERAZIN-1-YL-PYRIDIN-2-YLAMINO)-7H-PYRROLO[2,3-D]PYRIMIDINE-6-CARBOXYLIC ACID DIMETHYLAMIDE AND PROCESSES OF MAKING THEREOF | PKD2, SLC6A7, DHPS | MAPT 1550/4885POLB 1969/4885SMN1; SMN2 1136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.